This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
biotechnology: Archive
Buy 3 Momentum Anomaly Stocks as Markets Bask in Economic Strength
by Supriyo Bose
JWN, UHS and PGR are currently witnessing a short-term pullback in price. So, make sure you take full advantage of it.
UHSNegative Net Change PGRNegative Net Change
biotechnology insurance retail
Bayer Submits Application for Label Expansion of Prostate Cancer Drug
by Zacks Equity Research
BAYRY moves ahead with the submission of an application seeking approval of darolutamide in combination with androgen deprivation therapy in patients with metastatic hormone-sensitive prostate cancer.
REGNPositive Net Change PFEPositive Net Change LLYPositive Net Change BAYRYPositive Net Change
biotechnology medical pharmaceuticals
Bristol Myers Stock Up on FDA Nod for Schizophrenia Treatment
by Zacks Equity Research
The FDA approves BMY's differentiated schizophrenia treatment for adults and broadens its diverse portfolio. Shares gain.
BMYPositive Net Change ABBVPositive Net Change KRYSNegative Net Change FULCPositive Net Change
biotechnology biotechs medical pharmaceuticals
Atour Lifestyle Holdings Limited Sponsored ADR (ATAT) Just Flashed Golden Cross Signal: Do You Buy?
by Zacks Equity Research
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
ATATPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
BMEA Stock Up 9% as FDA Lifts Clinical Hold on 2 Diabetes Studies
by Zacks Equity Research
Biomea stock rises 9% after the FDA lifts clinical hold on two phase I/II studies evaluating the company's lead candidate, BMF-219, for diabetes.
ANIPNegative Net Change KRYSNegative Net Change FULCPositive Net Change BMEAPositive Net Change
biotechnology biotechs medical pharmaceuticals
Biotech Stock Roundup: BHVN, WVE, ZVRA Stocks Up on Updates, BIIB & UCBs Study Data & More
by Zacks Equity Research
Biohaven and Zevra are in the spotlight following positive updates on key candidates.
BIIBPositive Net Change VNDANegative Net Change WVEPositive Net Change BHVNPositive Net Change ZVRAPositive Net Change
biotechnology biotechs medical pharmaceuticals
CLDX Stock Down Despite Upbeat Long-Term Data From Urticaria Study
by Zacks Equity Research
Celldex stock falls due to safety concerns related to the treatment of urticaria patients with barzolvolimab in a phase II study, despite robust efficacy data.
CLDXPositive Net Change ANIPNegative Net Change KRYSNegative Net Change FULCPositive Net Change
biotechnology biotechs medical pharmaceuticals
Roche's Lupus Study for Gazyva Meets Primary & Key Secondary Goals
by Zacks Equity Research
RHHBY announces meeting primary and key secondary goals in the late-stage study of its lymphoma drug, Gazyva/Gazyvaro, for treating active lupus nephritis.
RHHBYPositive Net Change ANIPNegative Net Change KRYSNegative Net Change FULCPositive Net Change
biotechnology biotechs medical pharmaceuticals
After Golden Cross, Intercorp Financial Services Inc. (IFS)'s Technical Outlook is Bright
by Zacks Equity Research
Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?
IFSNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
TSVT, BMY Discontinue Enrollment in Late-stage Abecma Study
by Zacks Equity Research
2seventy bio and partner BMY decide to stop enrollment in the late-stage study on Abecma due to growth in the newly diagnosed multiple myeloma treatment space.
REGNPositive Net Change BMYPositive Net Change NVOPositive Net Change
biotechnology biotechs cell-therapy medical pharmaceuticals
Incyte Gains 12.7% Year to Date: How Should You Play the Stock?
by Zacks Equity Research
Though INCY's performance in the year so far has been good, increasing competition for Jakafi is a concern. We advise investors to wait and watch before turning positive.
GSKPositive Net Change NVSPositive Net Change INCYPositive Net Change
biotechnology biotechs medical pharmaceuticals
WVE Stock Soars on Upbeat Efficacy Data From Muscle Disease Study
by Zacks Equity Research
Wave Life Sciences stock soars 53% on positive interim data from a mid-stage study showing superior efficacy of investigational DMD drug, WVE-N531.
ANIPNegative Net Change WVEPositive Net Change KRYSNegative Net Change FULCPositive Net Change
biotechnology biotechs medical pharmaceuticals
Regeneron Stock Down on Court Ruling for Amgen's Biosimilar of Eylea
by Zacks Equity Research
A federal judge rejected Regeneron's request for a preliminary injunction against Amgen in its lawsuit for Eylea's biosimilar.
REGNPositive Net Change RHHBYPositive Net Change AMGNPositive Net Change BAYRYPositive Net Change
biotechnology biotechs medical pharmaceuticals
VTYX Stock Rises on Strategic Equity Investment Deal With SNY
by Zacks Equity Research
Ventyx stock climbs 7% on signing a $27 million strategic investment agreement with Sanofi in exchange for granting exclusive rights to VTX3232.
SNYPositive Net Change NVOPositive Net Change LLYPositive Net Change VTYXNegative Net Change
biotechnology biotechs medical pharmaceuticals
Regeneron, SNY's Dupixent Get CHMP Recommendation for Label Expansion
by Zacks Equity Research
REGN and SNY get positive CHMP opinion on the label expansion of Dupixent in the EU for eosinophilic esophagitis in children down to 1 year of age.
REGNPositive Net Change SNYPositive Net Change RHHBYPositive Net Change
biotechnology biotechs pharmaceuticals
Apellis Stock Down as Eye Drug Faces Third CHMP Rejection in the EU
by Zacks Equity Research
APLS stock falls as the CHMP confirms its June 2024 negative opinion on the regulatory filing for intravitreal pegcetacoplan to treat GA in the EU.
ILMNPositive Net Change KRYSNegative Net Change APLSPositive Net Change FULCPositive Net Change
biotechnology biotechs medical pharmaceuticals
NVO Stock Down on Unsatisfactory Data From Mid-Stage Obesity Study
by Zacks Equity Research
Novo Nordisk stock falls 5.5% on unsatisfactory safety and efficacy data from a mid-stage study of investigational obesity candidate, monlunabant.
NVOPositive Net Change LLYPositive Net Change VKTXNegative Net Change CRBPNegative Net Change
biotechnology biotechs medical pharmaceuticals
Kilroy Realty (KRC)'s Technical Outlook is Bright After Key Golden Cross
by Zacks Equity Research
Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?
KRCPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
NVO Stock Loses Around $29B in 3 Months: Buy the Dip or Steer Clear?
by Ahan Chakraborty
Despite the current downward trend of Novo Nordisk, it is an excellent stock to buy for long-term gains, driven by the stellar performance of its GLP-1 drugs.
NVOPositive Net Change LLYPositive Net Change AMGNPositive Net Change VKTXNegative Net Change
biotechnology biotechs medical pharmaceuticals
Roche Antiviral Drug Reduces Transmission in Late-stage Study
by Zacks Equity Research
Results from a late-stage study on RHHBY's Xofluza show that the drug reduces the transmission of influenza from an infected person to household members.
RHHBYPositive Net Change PFEPositive Net Change LLYPositive Net Change BAYRYPositive Net Change
biotechnology medical pharmaceuticals
Company News for Sep 20, 2024
by Zacks Equity Research
Companies In The News Are: PGNY, EWTX, FDS, SCS.
FDSNegative Net Change SCSNegative Net Change PGNYPositive Net Change EWTXPositive Net Change
biotechnology business-services medical
EWTX Stock Soars on Upbeat Efficacy Data From Cardiomyopathy Studies
by Zacks Equity Research
Edgewise stock soars on positive data from an early-stage study and Part A of a mid-stage study of EDG-7500 in obstructive hypertrophic cardiomyopathy patients.
ILMNPositive Net Change KRYSNegative Net Change FULCPositive Net Change EWTXPositive Net Change
biotechnology biotechs medical pharmaceuticals
APLT Stock Soars 69% on Positive Update on Galactosemia Drug NDA
by Zacks Equity Research
Applied Therapeutics stock surges 69% as the FDA says that no advisory committee meeting is required to discuss the govorestat NDA for classic galactosemia.
ILMNPositive Net Change KRYSNegative Net Change APLTPositive Net Change FULCPositive Net Change
biotechnology biotechs medical pharmaceuticals
Biotech Stock Roundup: GILD, NUVL Stocks Surge on Study Data, MRNA Down on Updates
by Zacks Equity Research
Gilead Sciences and Nuvalent are in the spotlight following positive updates on key candidates.
REGNPositive Net Change GILDNegative Net Change MRNAPositive Net Change ZNTLPositive Net Change NUVLNegative Net Change
biotechnology biotechs medical pharmaceuticals
ADMA Biologics Stock Soars 76.2% in 3 Months: Right Time to Invest?
by Ekta Bagri
ADMA stock surges 76.2% in three months on strong performance and high growth prospects. It recently hit its 52-week high with more room for growth.
GRFSNegative Net Change ADMAPositive Net Change TAKPositive Net Change
biotechnology biotechs medical pharmaceuticals